5月23日，截至港股收盘，恒生指数上涨0.24%，报23601.26点。福森药业（01652.HK）收报0.39港元/ 股，上涨30.0%，成交量430.9万股，成交额160.42万港元，振幅45.0%。 最近一个月来，福森药业累计涨幅11.11%，今年来累计跌幅62.5%，跑输恒生指数17.37%的涨幅。 财务数据显示，截至2024年12月31日，福森药业实现营业总收入3.26亿元，同比减少42.36%；归母净利 润-1.89亿元，同比减少420.39%；毛利率49.88%，资产负债率70.25%。 机构评级方面，目前暂无机构对该股做出投资评级建议。 资料显示，福森药业有限公司除提供核心产品双黄连类感冒药外,福森药业有限公司从事研发、生产及 销售多种用以治疗感冒及发热、心血管疾病及贫血的中成药及西药产品。福森药业有限公司对优质非处 方药及按现代剂型调配的处方中成药产品拥有专门知识。 （以上内容为金融界基于公开消息，由程序或算法智能生成，不作为投资建议或交易依据。） 本文源自：金融界 作者：行情君 行业估值方面，药品及生物科技行业市盈率（TTM）平均值为5.54倍，行业中值6倍。福森药业市盈 率-1.09倍， ...

央视网消息：民营经济促进法明确提出，国家鼓励、支持民营经济组织在推动科技创新、培育新质生产力、建设现代化产业体系中积极发挥作 用。2025年以来，融资、保险等金融要素资源，在投入民营企业的同时，产品设计也更加适配，为企业注入持续动能。 这家生物科技企业，主要从事细胞规模化生产及相关技术研发，是国家级专精特新"小巨人"企业。近期，企业计划升级核心技术，以覆盖更多 细胞品类，并探索全球化布局。这些业务的拓展都需要资金支持，但是这一次企业没有选择银行贷款，而是选择了金融资产投资公司的股权投 资。 区别于传统信贷，金融资产投资公司的股权投资，即AIC资金，不需要企业支付利息，可以降低企业的融资成本。同时，资金的投资周期较 长，能为这家企业提供持续的"耐心资本"支持。公司负责人表示，这笔股权投资的规模达到上亿元，目前相关业务已完成审批，即将签署协 议。 在AIC业务中，金融机构不再是传统的贷款提供方，而是从股东视角与企业共担风险，为企业提供综合的金融服务。 中国工商银行北京分行投资银行部副总经理刘洁介绍，他们不仅提供了账户结算、存贷款等基础保障服务，还为企业"量身定制"了一些创新金 融服务方案。此外，还会帮助企业对接更 ...

Market Overview - A-shares experienced slight fluctuations with major indices showing minor gains, including the Shanghai Composite Index rising for the fourth consecutive day [1] - The trading volume continues to shrink, indicating a potential decrease in market activity [1] Key Indices Performance - Shanghai Composite Index: 3,382.96 (+0.08%) - Shenzhen Component Index: 10,271.21 (+0.50%) - ChiNext Index: 2,055.44 (+0.48%) - Shanghai 50 Index: 2,738.01 (+0.16%) - CSI 300 Index: 3,925.58 (+0.30%) - STAR 50 Index: 993.56 (+0.29%) - North Exchange 50 Index: 1,410.71 (+1.58%) - CSI 1000 Index: 6,079.58 (+0.22%) [2] Pharmaceutical Sector - The pharmaceutical sector showed strong performance with significant gains in various sub-sectors, including AI healthcare and weight loss drugs, with some stocks reaching their daily limit [3] - Hengrui Medicine's H-shares debuted on the Hong Kong Stock Exchange, surging over 37% during trading, raising approximately HKD 9.9 billion, marking the largest IPO in the Hong Kong pharmaceutical sector in five years [5] Innovation in Pharmaceuticals - China's pharmaceutical industry is rapidly developing, with exports reaching USD 26.632 billion in Q1 2025, a 4.39% increase year-on-year, while imports decreased by 4.42% to USD 20.456 billion [7] - The number of active innovative drugs developed by Chinese companies reached 3,575 by the end of 2024, ranking first globally, with domestic products accounting for 42% of approved innovative drugs [7] Automotive Industry - The automotive supply chain was active, with various segments such as passenger cars and automotive components showing strong gains [8] - The passenger car market saw sales of 6.872 million units from January to April, a 7.9% increase year-on-year, while the new energy vehicle market experienced a 35.7% increase with sales of 3.324 million units [10] Solid-State Battery Developments - The solid-state battery sector received positive news, with the China Automotive Engineering Society releasing standards for solid-state batteries, facilitating technological upgrades [11] - Companies like Funeng Technology and Guoxuan High-Tech are making significant advancements in solid-state battery development, with plans for commercial delivery of products by the end of 2025 [11]

| 15:00-15:30 | Building AI Virtual Cells (AIVC) with | | --- | --- | | | perturbation proteomics and active | | | learning 郭天南 西湖大学医学院和生命科学学院长聘副教授 | | 15:30-16:00 | Al for Science 行业探索和展望 | | | 冯小平 北京智谱华章科技有限公司 CIT创新中心负责人 | | 16:00-16:30 自然语言驱动,实验设计一步到位 | | | | Opentrons Al 让自动化触手可及 | | | 原非 Opentrons 全国销售总监 | | 16:30-17:00 | 深势科技 Al for Science | | | 医药研发数智化平台 | | | 李厦戎 深势科技 AI4S生命科学方案总监 | 90天 | 西湖大学医学院和生命科学学院长聘副教授 郭天南,西湖大学医学院、生命科学学院博士生导师、长聘 副教授,西湖大学蛋白质组复杂科学实验室负责人,西湖实 验室智能蛋白质组中心(WeCIP)主任,西湖大学未来产业 研究中心兼聘研究 ...

西风 发自 凹非寺 量子位 | 公众号 QbitAI 无特效疗法、无法根治的疾病，现在被「AI科学家」发现了潜在新疗法。 核 心流程完全由 AI驱动 ，人类研究员仅执行了实验室实验和最终论文撰写的那种。 最近非营利性组织Future House宣布了一个最新成果： 可以致盲的眼部疾病—— 干 性年龄相关 性黄斑变性 （dAMD） ，或许有救了。 他们用一个 多智能体系统 ，成功锁定 Ripasudil 这种已在日本获批用于临床治疗青光眼的ROCK抑制剂，对这种病具有潜在治疗效果。 团队咨询了多位有关此疾病领域的专家，均对这一发现的创新性和价值持认可态度。 重要的是，除实验室实际物理实验操作和最终手稿撰写外，论文形成所需的核心环节均由智能体完成，包括提出假设、实验设计、数据分析到 迭代优化的全流程。 甚至Agent还协助完成了论文图表的绘制。 整个研究仅耗时约10周 ，远短于研究团队手动完成所有计算机模拟环节的时间。 团队还特别说明，他们此前从未在其他文献中发现有人提出使用ROCK抑制剂治疗dAMD： 如果没有这些Agent，我们很难提出这一假设。 另外研究团队还表示， 将在下周开源代码和数据 。 这一成果公布 ...

Group 1 - The major industry ETFs in the US stock market showed mixed performance, with the Utilities ETF declining approximately 2% and the Energy ETF dropping over 1% [1] - The Utilities ETF (US XLU) was reported at 79.62, down by 1.64 (-2.02%) with a trading volume of 2.653 million shares and a market capitalization of 11.559 billion [2] - The Energy ETF (US XLE) was at 81.10, down by 0.95 (-1.16%) with a trading volume of 1.652 million shares and a market capitalization of 20.309 billion [2] Group 2 - The Gold ETF (US GLD) was priced at 303.77, down by 2.05 (-0.67%) with a trading volume of 1.578 million shares and a market capitalization of 82.170 billion [2] - The Healthcare ETF (US XLV) was at 130.94, down by 0.65 (-0.49%) with a trading volume of 1.9005 million shares and a market capitalization of 25.056 billion [2] - The Biotechnology ETF (US IBB) was priced at 121.15, down by 0.54 (-0.44%) with a trading volume of 90,342 shares and a market capitalization of 9.619 billion [2] Group 3 - The Consumer Staples ETF (US XLP) was at 81.31, down by 0.33 (-0.40%) with a trading volume of 1.3075 million shares and a market capitalization of 13.759 billion [2] - The Regional Banks ETF (US KRE) was priced at 56.50, down by 0.15 (-0.26%) with a trading volume of 1.8414 million shares and a market capitalization of 4.715 billion [2] - The Financials ETF (US XLF) was at 50.19, down by 0.10 (-0.21%) with a trading volume of 3.0012 million shares and a market capitalization of 55.858 billion [2] Group 4 - The Consumer Discretionary ETF (US XLY) was priced at 211.89, up by 0.24 (+0.11%) with a trading volume of 288,200 shares and a market capitalization of 26.614 billion [2] - The Global Technology ETF (US IXN) was at 83.87, up by 0.18 (+0.22%) with a trading volume of 6,472 shares and a market capitalization of 1.174 billion [2]

今天主要是小微盘迎来了调整，尤其是北证50，今天大跌6.15%，不过这个单日跌幅，在北交所 开板的短短3年时间内，只能排到第10，光2024年一年，北证50跌幅超过6%的天数就有6天，也就 是说，这玩意儿波动本来就大。 如果要找理由的话，我总结了一下，主要有以下三个。 第一，近期舆论上，提醒大家注意小微盘风险的声音越来越多，尤其是不少基金经理，开始把旗 下的小微盘基金做限购，换句话说，比较有敬畏心的一批基金经理，自己都有点怕了，所以一部 分资金可能在坚定地 提前止盈 ，想跑到前面，特别是北证50这种，昨天刚刚刷出历史新高的； 第二，指数估值层面， 确实是贵 ，我给大家盘盘——截止上周五最新的滚动市盈率， 北证50是 76倍，在历史最高位；中证2000是136倍，比近10年内98%以上的时间都贵；科创50是140倍，比 开板以来99%以上的时间都贵，也是极值水平了；微盘股就不用说了，也在历史极值水平——换 句话说，再往上涨，都属于无人区了； 第三，但今天只有北证50跌得比较狠，微盘股和中证2000都只跌了1个点出头，这可能是因为北 证50的第一大成分股 ，占比10%的 锦波生物 ，大跌了15%左右（公司最近，还 ...

Summary of Key Points Core Viewpoint - The company, Beijing Yingtai Jiahe Biotechnology Co., Ltd., announced the lifting of restrictions on the sale of 6,002,500 shares, which represents 0.49% of the total share capital [1]. Details of Restricted Stock Release - The total number of shares released from restrictions is 6,002,500 shares, accounting for 0.49% of the company's total share capital of 1,225,800,000 shares [2]. - The reasons for the release of restrictions include annual releases for directors, supervisors, and senior management, as well as releases due to the departure of these individuals [2]. Post-Release Share Capital Situation - After the release of restrictions, the total number of unrestricted shares is 1,207,582,500, which constitutes 98.51% of the total share capital [2]. - The total number of restricted shares remaining is 18,217,500, representing 1.49% of the total share capital [2]. Other Relevant Information - There are no outstanding commitments from the shareholders applying for the release of restrictions [2]. - There are no non-operational fund occupations by the shareholders applying for the release of restrictions [2]. - The company has confirmed that there are no violations or guarantees that could harm the company's interests related to the shareholders applying for the release [2].

Core Viewpoint - The report indicates that Hangzhou Anxu Biotechnology Co., Ltd. has maintained a sound governance structure and effective internal controls during the continuous supervision period, with no violations in fundraising, related transactions, or operational status [1][5]. Group 1: Company Governance and Internal Control - The company’s articles of association and governance systems are complete and effectively executed [2]. - The board of directors, supervisors, and senior management fulfill their responsibilities as required [2]. - Internal control systems are effectively implemented [2]. Group 2: Information Disclosure - The company has fulfilled its information disclosure obligations accurately and completely, with no false records or misleading statements [2][5]. Group 3: Independence and Related Party Transactions - The company maintains independence in assets, personnel, finance, and business, with no violations regarding the occupation of company funds by related parties [3][4]. Group 4: Fundraising and Usage - The company has adhered to fundraising management regulations, with funds stored in dedicated accounts and no unauthorized changes in usage [3][4]. Group 5: Related Transactions and Investments - There are no violations regarding external guarantees, related transactions, or significant external investments during the supervision period [4][5]. Group 6: Operational Status - The company’s business model and structure have not undergone significant adverse changes, and its operational status remains normal [4][5]. Group 7: Compliance and Recommendations - The company is advised to continue improving its governance structure and ensure timely information disclosure while managing fundraising effectively [5].

Core Viewpoint - Ningxia Zhongke Biotechnology Co., Ltd. is facing significant financial distress, with a total debt of 2.164 billion yuan and overdue debts amounting to 1.81 billion yuan, leading to a serious risk of bankruptcy [1][5]. Group 1: Debt and Financial Status - The company's total debt scale is 2.164 billion yuan, with overdue debts totaling 1.81 billion yuan and litigation-related debts amounting to 1.26 billion yuan [1][5]. - Most of the company's bank accounts, except for those of its subsidiary Ningxia Huahui Environmental Technology Co., Ltd. and its wholly-owned subsidiary Ningxia Tianfu Activated Carbon Co., Ltd., are frozen, severely impacting its liquidity [1][5]. - Although the bank accounts of Zhongke New Materials Co., Ltd. have been unfrozen, the company is currently lacking sufficient funds and liquid assets to repay its debts, indicating a significant risk to its ongoing operations [1][5]. Group 2: Litigation Status - The company is a defendant in multiple lawsuits, including disputes over loan contracts, equity transfer contracts, sales contracts, construction contracts, and securities fraud [2][5]. - A recent court ruling from the Guangdong Zhanjiang Intermediate People's Court dismissed the claims made by Guangdong Nanyue Bank against the company, stating that the bank failed to verify the public disclosure of the guarantee matters [3][5]. - The court supported the company's defense regarding the "maximum pledge contract," ruling that it does not have legal effect, thus not impacting the company's current or future profits [3][5].